Optimization of globomycin analogs as novel gram-negative antibiotics.

导出原文传递

翻译打印收藏纠错

作者： Keira,Garland ^[1] ; Homer,Pantua ^[1] ; Marie-Gabrielle,Braun ^[1] ; Daniel J,Burdick ^[1] ; Georgette M,Castanedo ^[1] ; Yi-Chen,Chen ^[1] ; Yun-Xing,Cheng ^[2] ; Jonathan,Cheong ^[1] ; Blake,Daniels ^[1] ; Gauri,Deshmukh ^[1] ; Yuhong,Fu ^[2] ; Paul,Gibbons ^[1] ; Susan L,Gloor ^[1] ; Rongbao,Hua ^[2] ; Sharada,Labadie ^[1] ; Xiongcai,Liu ^[2] ; Richard,Pastor ^[1] ; Craig,Stivala ^[1] ; Min,Xu ^[1] ; Yiming,Xu ^[1] ; Hao,Zheng ^[1] ; Sharookh B,Kapadia ^[1] ; Emily J,Hanan ^[3]

作者单位： Genentech, Inc., 1 DNA Way, South San Francisco, CA 94080, USA. ^[1] Pharmaron Beijing Co., Ltd, No. 6 Taihe Road, BDA, Beijing 100176, PR China. ^[2] Genentech, Inc., 1 DNA Way, South San Francisco, CA 94080, USA. Electronic address: hanan.emily@gene.com. ^[3]

关键词 Globomycin Gram-negative LspA Signal peptidase

主题词抗菌药(Anti-Bacterial Agents);剂量效应关系, 药物(Dose-Response Relationship, Drug);大肠杆菌(Escherichia coli);微生物敏感性试验(Microbial Sensitivity Tests);分子结构(Molecular Structure);肽类(Peptides);构效关系(Structure-Activity Relationship)

DOI 10.1016/j.bmcl.2020.127419

PMID 32768648

发布时间 2021-06-22

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交